Guggenheim Upgrades Surrozen on Promising Liver Disease Data
Guggenheim upgrades Surrozen (SRZN) following promising Phase 1b trial results for its lead liver disease asset. Explore implications for SRZN stock.
Topic
liver disease
A collection of 1 issue